

Q-linea signs UK distribution partnership

Q-linea AB (publ) (OMX: QLINEA) today announces that the company has signed a distribution partnership for ASTar Instrument and consumables for the UK market with Pro-Lab Diagnostics.

Q-linea's updated marketing strategy includes, among other things, collaborations to achieve a broader reach for ASTar via distribution partnerships. Q-linea has signed a distribution agreement for the UK market with Pro-Lab Diagnostics as sole distribution partner, however, Q-linea also has the right to address this market. The agreement is based on a transfer price model with yearly performance targets to be assessed by Q-linea.

"Antimicrobial resistance continues to present a challenge to the diagnostics industry and its rapid and accurate management is of paramount importance. We are delighted to partner with Q-linea in the UK and look forward to introducing this exciting technology into the fight against sepsis," said Mark Reed, General Manager of Pro-Lab Diagnostics.

"I am really pleased that we are taking the first step in our updated commercialisation strategy with Pro-Lab Diagnostics. We have known them for several years and their deep expert knowledge in the microbiology space is truly impressive. The UK market is one of our priorities for 2023, both regarding size and the interest we have seen so far and because it is a leading region when it comes to sepsis awareness. I look forward to seeing how we together can approach the UK market and I expect to see traction during 2023," said Jonas Jarvius, CEO of Q-linea.

About Pro-Lab Diagnostics

Pro-Lab Diagnostics is based in Canada, but also has operation in the US and UK. The company was formed in Canada in 1974 and the UK subsidiary was formed in 1989. The team is around 100 people and has a deep understanding and history in the microbiology market.

About ASTar Instruments and ASTar BC G-Kit

ASTar Instrument and ASTar BC G-Kit already deliver the broadest answer regarding the combination of the number of antibiotics and the number of double dilution steps of each antibiotic, in a single analysis for gram-negative bacteria. The test enables the analysis of gram-negative bacteria, including difficult-to-grow so-called fastidious bacteria, which satisfies the need for rapid and comprehensive results to support optimal treatment decisions.

ASTar Instrument and ASTar BC G-Kit are CE-marked but not FDA 510(k)-cleared and not available for sale in the United States.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

[Q-linea signs UK distribution partnership](#)